.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The SENOMAC randomized clinical trial evaluated whether completion axillary lymph-node dissection could be omitted in women with breast cancer who had limited sentinel-node metastases. The study found very similar recurrence-free outcomes between patients who underwent axillary dissection and those managed without it, supporting a less invasive approach for appropriately selected patients. The clinical significance is substantial because axillary dissection can cause long-term morbidity, including lymphedema, pain and shoulder dysfunction. For breast surgeons, the message is that the presence of limited sentinel-node disease does not automatically mandate a more extensive axillary operation. Patient selection and the broader treatment context remain crucial, including tumor biology, systemic therapy, radiotherapy and the extent of nodal disease. The trial strengthens the move toward de-escalation of surgery where equivalent cancer control can be maintained. It also reinforces the role of multidisciplinary breast teams in integrating surgical, radiation and systemic treatment decisions rather than making the axillary procedure in isolation.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The SENOMAC randomized clinical trial evaluated whether completion axillary lymph-node dissection could be omitted in women with breast cancer who had limited sentinel-node metastases. The study found very similar recurrence-free outcomes between patients who underwent axillary dissection and those managed without it, supporting a less invasive approach for appropriately selected patients. The clinical significance is substantial because axillary dissection can cause long-term morbidity, including lymphedema, pain and shoulder dysfunction. For breast surgeons, the message is that the presence of limited sentinel-node disease does not automatically mandate a more extensive axillary operation. Patient selection and the broader treatment context remain crucial, including tumor biology, systemic therapy, radiotherapy and the extent of nodal disease. The trial strengthens the move toward de-escalation of surgery where equivalent cancer control can be maintained. It also reinforces the role of multidisciplinary breast teams in integrating surgical, radiation and systemic treatment decisions rather than making the axillary procedure in isolation.
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
